Avellino Lab USA, Menlo Park, Calif, has introduced the Avellino DNA Dual Test for LASIK Safety, a genetic test that detects Avellino Corneal Dystrophy (ACD) and Granular Corneal Dystrophy type I (GCD1). Caused by a genetic mutation, GCD1 is a slow-developing condition characterized by small translucent dots that form in the layers of the cornea. Many patients display no physical symptoms until later in life, but GCD1 can lead to blindness if patients with the condition undergo vision correction surgery. The Avellino DNA Dual test allows patients to determine if they have GCD1 or ACD (also known as GCD2) prior to undergoing LASIK, avoiding the risk of postsurgery vision complications. The test is conducted via a mouth swab, with the sample sent to Avellino’s CLIA-certified facility for analysis. Results are typically provided in 24 to 48 hours. For more information, visit Avellino Lab USA.